CJC-1295 with DAC tracker

CJC-1295 with DAC incorporates a drug affinity complex that covalently attaches to albumin, extending its plasma half-life to approximately 7 days. This modification allows once-weekly dosing while maintaining continuous GHRH receptor stimulation. The DAC form produces sustained GH pulse amplification over days, which differs significantly from the pulsatile profile of non-DAC GHRH analogues. The extended half-life means longer washout periods if side effects occur. Systematic tracking of GH-related symptoms, injection site reactions, and concomitant compound timing is particularly important for this long-acting peptide.